533 related articles for article (PubMed ID: 8932836)
1. Phase I study of high-dose etoposide phosphate in man.
Fields SZ; Budman DR; Young RR; Kreis W; Ingram R; Schulman P; Cherny RC; Wright J; Behr J; Snow C; Schacter LP
Bone Marrow Transplant; 1996 Nov; 18(5):851-6. PubMed ID: 8932836
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of etoposide phosphate administered as a daily 30-minute infusion for 5 days.
Thompson DS; Greco A; Miller AA; Srinivas NR; Igwenezue KB; Hainsworth JD; Schacter LP; Kaul S; Barbhaiya RH; Garrow C
Clin Pharmacol Ther; 1995 May; 57(5):499-507. PubMed ID: 7768072
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of etoposide phosphate (etopophos) as a 30-minute infusion on days 1, 3, and 5.
Fields SZ; Igwemezie LN; Kaul S; Schacter LP; Schilder RJ; Litam PP; Himpler BS; McAleer C; Wright J; Barbhaiya RH
Clin Cancer Res; 1995 Jan; 1(1):105-11. PubMed ID: 9815892
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of high-dose melphalan, high-dose etoposide and autologous bone marrow re-infusion in solid tumors: an Eastern Cooperative Oncology Group (ECOG) study.
Lazarus HM; Gray R; Ciobanu N; Winter J; Weiner RS
Bone Marrow Transplant; 1994 Sep; 14(3):443-8. PubMed ID: 7994270
[TBL] [Abstract][Full Text] [Related]
5. Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: a cancer research campaign phase I/II committee study.
Porter D; Boddy A; Thomas H; Lind M; Newell D; Calvert AH; Robson L; Brampton M; Abrahamsen D; Winograd B
Semin Oncol; 1996 Dec; 23(6 Suppl 13):34-44. PubMed ID: 8996574
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic evaluation of high-dose etoposide phosphate after a 2-hour infusion in patients with solid tumors.
Kreis W; Budman DR; Vinciguerra V; Hock K; Baer J; Ingram R; Schacter LP; Fields SZ
Cancer Chemother Pharmacol; 1996; 38(4):378-84. PubMed ID: 8674162
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
8. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
9. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
10. Clinical studies with etoposide phosphate.
Greco FA; Hainsworth JD
Semin Oncol; 1996 Dec; 23(6 Suppl 13):45-50. PubMed ID: 8996575
[TBL] [Abstract][Full Text] [Related]
11. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
12. A phase I dose escalation study of multicyclic, dose-intensive chemotherapy with peripheral blood stem cell support for small cell lung cancer.
Takahashi M; Yoshizawa H; Tanaka H; Tanaka J; Kagamu H; Ito K; Shimbo T; Chou D; Wakabayashi M; Suzuki E; Sakai K; Arakawa M; Gejyo F
Bone Marrow Transplant; 2000 Jan; 25(1):5-11. PubMed ID: 10654007
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of high-dose continuous intravenous infusion of VP-16 in combination with high-dose melphalan followed by autologous bone marrow transplantation in children with stage IV neuroblastoma.
Valteau-Couanet D; Vassal G; Pondarré C; Bonnay M; Benhamou E; Couanet D; Plantaz D; Hartmann O
Bone Marrow Transplant; 1996 Apr; 17(4):485-9. PubMed ID: 8722343
[TBL] [Abstract][Full Text] [Related]
14. Phase I evaluation of a water-soluble etoposide prodrug, etoposide phosphate, given as a 5-minute infusion on days 1, 3, and 5 in patients with solid tumors.
Budman DR; Igwemezie LN; Kaul S; Behr J; Lichtman S; Schulman P; Vinciguerra V; Allen SL; Kolitz J; Hock K
J Clin Oncol; 1994 Sep; 12(9):1902-9. PubMed ID: 8083713
[TBL] [Abstract][Full Text] [Related]
15. Phase I evaluation of therapy with four schedules of 5-fluorouracil by continuous infusion combined with recombinant interferon alpha.
Greenblatt MS; Mangalik A; Ferguson J; Elias L
Clin Cancer Res; 1995 Jun; 1(6):615-20. PubMed ID: 9816023
[TBL] [Abstract][Full Text] [Related]
16. Dose escalation of the hypoxic cell sensitizer etanidazole combined with ifosfamide, carboplatin, etoposide, and autologous hematopoietic stem cell support.
Elias AD; Wheeler C; Ayash LJ; Schwartz G; Ibrahim J; Mills L; McCauley M; Coleman N; Warren D; Schnipper L; Antman KH; Teicher BA; Frei E
Clin Cancer Res; 1998 Jun; 4(6):1443-9. PubMed ID: 9626461
[TBL] [Abstract][Full Text] [Related]
17. A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors.
Dees EC; Whitfield LR; Grove WR; Rummel S; Grochow LB; Donehower RC
Clin Cancer Res; 2000 Oct; 6(10):3885-94. PubMed ID: 11051234
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies.
Tolcher AW; O'Shaughnessy JA; Weiss RB; Zujewski J; Myhand RC; Schneider E; Hakim F; Gress R; Goldspiel B; Noone MH; Brewster LR; Gossard MR; Cowan KH
Clin Cancer Res; 1997 May; 3(5):755-60. PubMed ID: 9815746
[TBL] [Abstract][Full Text] [Related]
19. High-dose carboplatin, etoposide and cyclophosphamide with autologous bone marrow transplantation for the treatment of advanced malignancies: a phase I study.
Saez RA; Slease RB; Strnad C; Selby GB; Confer DL; Epstein RB
Bone Marrow Transplant; 1995 Oct; 16(4):507-14. PubMed ID: 8528165
[TBL] [Abstract][Full Text] [Related]
20. A pharmacodynamic evaluation of hematologic toxicity observed with etoposide phosphate in the treatment of cancer patients.
Kaul S; Srinivas NR; Igwemezie LN; Barbhaiya RH
Semin Oncol; 1996 Dec; 23(6 Suppl 13):15-22. PubMed ID: 8996571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
